StockData
Biohaven Ltd. logo

Biohaven Ltd. (BHVN) stock

BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 1/30
$13.82−0.25 (-1.78%)

Close on Nov 13, 2026Market cap $2.09BP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$2.09B
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
-22.67%

Fundamentals

Net income
-$542.68M
EPS, diluted
-$3.86
Free cash flow
-$473.17M
Book value per share
-$0.65
Diluted shares
151M

Trading

Next earnings
Mar 1, 2027 (estimated, after the close)
Previous close
$14.07
Open
$14.29
Day's range
$13.37 – $14.29
Volume
1,257,764
Average volume (20 days)
3,815,790
Beta (5 years)
1.60
52-week range
$7.78 – $18.24
RSI (14 days)
47.8
Volatility (1 year)
82.8%
Relative volume
0.44×
WACC
12.2%

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodBHVNS&P 500DifferenceBHVN per yearS&P 500 per year
1 month+21.0%-3.0%+24.1 pts
3 months-6.9%-2.8%−4.2 pts
Year to date+22.4%+11.5%+10.9 pts
1 year+71.0%+13.5%+57.6 pts
3 years-52.0%+77.7%−129.7 pts-21.7%+21.1%
5 years-88.7%+72.6%−161.3 pts-35.3%+11.5%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Operating income

-$524.48M

Net income

-$542.68M

EPS, diluted

-$3.86

Free cash flow

-$473.17M
Reported periodTrailing twelve months

Press releases

Releases Biohaven filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Biohaven

Pharmaceutical Preparations

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological, immunological, and metabolic conditions. The company advances several clinical-stage drug candidates across multiple therapeutic platforms. Key investigational assets include BHV-1300 and BHV-1400, which are extracellular protein degraders under development for autoimmune diseases such as Graves' disease and IgA nephropathy. It also develops opakalim, a potassium channel activator for epilepsy, and taldefgrobep alfa, an investigational agent targeting obesity and neuromuscular disorders. Biohaven's potential treatments are designed for patients affected by serious central nervous system, autoimmune, and metabolic disorders.

Company profile, executives and history

Biohaven stock: common questions

What is Biohaven's stock price?

BHVN closed at $13.82 on Nov 13, 2026, down 1.78% on the day. Over the past 52 weeks it traded between $7.78 and $18.24.

What is Biohaven's market cap?

Biohaven was worth $2.09B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is BHVN's P/E ratio?

Biohaven lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.86), so it has no meaningful P/E ratio.

Does Biohaven pay a dividend?

No. Biohaven has not paid a cash dividend over the last twelve months.

When does Biohaven report earnings next?

Biohaven is expected to report Q4 FY2026 results on Mar 1, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has BHVN stock performed over the past year?

Including dividends, BHVN returned +71.0% over the past year, against +13.5% for the S&P 500.

How many BHVN shares are sold short?

15M shares were sold short at the latest FINRA report, 11.54% of the float, or 2.9 days of average trading volume.

Who are Biohaven's competitors?

Companies most similar to Biohaven by business, industry and size include XENE, OVID, ANRO, PRAX, ANVS.

See a number that looks wrong?